The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

Thu, 12th May 2022 19:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Syncona Ltd - investor in healthcare companies - portfolio company, Autolus Therapeutics PLC to present data at European Hematology Association's Congress on June 9-12. Data includes positive early safety and efficacy data from AUTO4 in T cell lymphoma, and promising early data in AUTO1/22 programme in paediatric acute lymphoblastic leukaemia, as well as AUTO1 early safety and efficacy for relapsed/refractory primary central nervous system lymphoma.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Will present data on the potential of bexmarilimab in combination with standard of care for blood cancers at the European Hematology Association's Congress. Bexmarilimab is its wholly-owned novel precision cancer immunotherapy. It targets the Clever-1 receptor, which is associated with tumour-associated macrophages. "High Clever-1 expression is associated with poor survival in certain blood cancer patients and bexmarilimab provides a novel treatment approach for these patients, downregulating Clever-1 expression and igniting an effective immune response. We look forward to the imminent start of our hematology cancer clinical trial program to further explore these promising findings," says Chief Medical Officer Marie-Louise Fjallskog.

----------

Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Results blinded, international, multi-centre validation study for Tuteva blood test showed significantly higher Positive Predictive Value for Tuteva than currently available kidney transplant blood tests. "The results reflect the wide clinical applicability of the test for comprehensive commercial adoption in a real-world setting," Verici says.

----------

Water Intelligence PLC - London-based leak detection services - Reacquires franchise in central Texas held within American Leak Detection subsidiary for USD750,000 cash, building upon acquisition of Forth Worth, Texas franchise in January. "The group is executing this regional hub model across the United States with its more than 150 corporate and franchise locations," the company says.

----------

Graft Polymer (UK) PLC - Slovenia-based polymer modification and drug delivery systems -Is granted Hazard Analysis & Critical Control Point certificate for its R&D facility in Slovenia for GraftBio division. "The HACCP certificate will allow us to create a strong reputation in the B2C market as a manufacturer of quality and safe food supplements, selling direct to consumers over time - a more lucrative revenue stream," says Chief Executive Officer Victor Bolduev.

----------

React Group PLC - South Derbyshire, England-based cleaning, hygiene and decontamination firm - Completes acquisition of window, gutter and cladding business LaddersFree Ltd for up to GBP8.5 million. GBP4.7 million is paid in cash, with GBP1.0 million in 83.3 million new ordinary shares at 1.2 pence each. Deferred consideration of GBP1.5 million to be paid in instalments. The acquired company has a "consistent track record of organic revenue growth and profitability", React says, and will broaden its customer base, reducing dependence on reactive and ad hoc work.

----------

AEX Gold Inc - Greenland-focused gold miner - Acquires mineral exploration licences No. 2020-41 and 2021-11 covering areas in south Greenland from Orano Group for no upfront consideration but a royalty on future production. The acquisition means AEX will be the largest licence holder in region, and the third-largest in Greenland, after Anglo American PLC and Greenfield Exploration. "We are excited to be substantially increasing our exposure to strategic metals and rare earth elements across Greenland. Greenland has the potential to become a crucial supplier of these vital minerals to the Western world, and AEX intends to be a key player in this," says Chief Executive Officer Eldur Olafsson.

----------

Puma VCT 12 PLC - venture capital trust managed by Puma Investments - Announces Sunlight Education Nucleus Ltd has been acquired, in which it invested GBP2.4 million in 2017. Exit represents 3.2 times return on its equity investment.

----------

Avation PLC - Singapore-based passenger aircraft leasing company - Completes second sale of series of ex-Virgin Australia Airlines ATR72-600s to Aegean Airlines for unspecified amount. Executive Chair Jeff Chatfield says: "Avation continues to reduce its few remaining unutilised aircraft in the fleet. We anticipate zero unutilised aircraft by the end of the calendar year 2022. Sales of unutilised aircraft provide capital to rebuild in a post-pandemic recovery phase."

----------

Belluscura PLC -London-based medical device developer - Will raise GBP5 million in accelerated bookbuild via placing of new shares. Proceeds will be used to fund the purchase of raw material inventory and non-recurring costs of manufacturing and engineering, in relation to its manufacturing agreement with InnoMax Medical Technology Ltd. Dowgate Capital Ltd is acting as sole placing agent, bookrunner and broker, with SPARK Advisory Partners Ltd acting as nominated adviser.

----------

Circle Property PLC - London-based buyer, developer and manager of regional office assets in UK - Has exchanged contracts for the sale of 720 Aztec West in Bristol to Maybrook Properties Ltd. Sale price of GBP2.5 million is a 77% increase on the valuation of GBP1.4 million at the end of March last year.

----------

Clontarf Energy PLC - Dublin-headquartered oil & gas exploration and production company focused on South America and Africa - Updates on drilling for Sasanof-1 exploration well. Says Valaris MS-1 rig is anchored in Dampier outer harbour, scheduled to commence tow to Sasanof-1 location on Monday. The operator Western Gas' drilling operations dteam are deployed to field and with now onboard MS-1 rig and undertake pre-mobilisation checks. Support vessels started operations on time on Monday. Drilling operations are expected to start on May 24. Has 10% working interest in Sasanof.

----------

Molten Ventures PLC - London-based venture capital firm focused on technology companies - Says portfolio company Aiven, a Finnish software company, closes externally-led series D funding round, raising USD210 million. Valuation of Aiven now USD3 billion, a "significant uplift on earlier rounds". Molten holds interest through Earlybird Partnership. Says carrying value of its holding in Aiven will be finalised as part of its final results on June 13.

----------

Mercia Asset Management PLC - regionally focused specialist asset manager – Says Knowledge-Intensive and annual Enterprise Investment Scheme funds raise total of around GBP20 million in new capital over past year.

----------

Kefi Gold & Copper PLC - Cyprus-based gold and copper exploration and development company with projects in Ethiopia and Saudi Arabia - Says progress in Ethiopia remains on track over past month, and multi-party project financing is developing. Expects to sign umbrella financing agreement this quarter, with full construction to commence from October, at the end of the current wet season. "KEFI has been able to pivot onto a much more positive direction since December 2021 due to geopolitics, regulatory changes and exploration results. We now have three advanced projects in two countries that are now overtly pro-development - a more positive and less risky position than KEFI has confronted for many years," says Executive Chair Harry Anagnostaras-Adams.

----------

European Metals Holdings Ltd - mineral exploration and development company focused on Cinovec lithium-tin project in Czech Republic - Accepted to trade on US based OTCQX Best Market, under the codes "EMHXY", "ERPNF" and "EMHLF" from Thursday. "Trading on the OTCQX comes at a pivotal time for investors seeking to leverage the transition away from fossil fuels, with the European Union offering significant funding to accelerate change and adoption rates of electric vehicles in the region continuing to climb," says Executive Chair Keith Coughlan.

----------

Future Metals NL - Perth-based platinum exploration company - Reports wide PGM assay results from drillhole samples at 100%-owned Panton PGM Project in northern Western Australia. Highlights include 60.5 metres at 1.24 grams per tonne palladium equivalent from 0 metres. "All drill hole results returned to date have confirmed significant intercepts of mineralisation, demonstrating the strong continuity of the Panton orebody along its current 3.5km strike, and the lateral extent of mineralisation sitting outside of the chromite reefs," says Chief Executive Officer & Managing Director Jardee Kininmonth. Is targeting new mineral resource estimate release in the coming weeks.

----------

Destiny Pharma PLC - Brighton-based clinical phase biotechnology company - Says data previously reported for c. difficile infection model study is accepted for presentation at Anaerobe 2022 Conference in Seattle. Data is on the ability of non-toxigenic strain M3 to colonise the gut following antibiotics. "The relevance and impact of this study cannot be underestimated as it indicates that the clinical use of fidaxomicin to treat CDI is unlikely to affect the ability of Destiny's late-stage asset, NTCD-M3, to colonise the gut and prevent recurrence of CDI," explains Chief Scientific Officer Bill Love.

----------

Mattioli Woods PLC - Leicester, England-based asset manager - Says subsidiary Ludlow Wealth Management Group Ltd has acquired Ferguson Financial Management Ltd for an initial GBP600,000 and potential further consideration of up to GBP600,000 million dependent on the attainment of performance targets in the year after completion.

----------

Capital Metals PLC - developing eastern minerals project in Sri Lanka - Says study for project demonstrates "exceptional economics" resulting in a high margin operation, enabling a short payback period. Says the long-term price assumptions used are below current prices suggesting "even more attractive economics are feasible". Further, it says the study does not take into account any potential resource extensions, which would enable the expansion of mine life and throughput, providing even further upside.

----------

HeiQ PLC - Zurich-based materials developer - Will pay deferred considerations relating to acquisitions of RAS AG and Life Material Technologies Ltd. Will pay EUR2.6 million to RAS based on its annual performance through ordinary shares of 30 pence each in HeiQ capital. Will pay USD2.8 million to Life, settled half in cash and half in new ordinary shares. Total new shares allotted for the transactions are 3.5 million.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
9 Mar 2020 10:26

Faron gets FDA tick from proposed design of next 'Traumakine' study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.

Read more
5 Mar 2020 14:28

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Read more
2 Mar 2020 12:04

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Read more
2 Mar 2020 10:08

Faron Pharmaceuticals acquires rights to AOC3 inhibitors

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application.

Read more
6 Feb 2020 14:17

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Read more
27 Jan 2020 11:22

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Read more
13 Jan 2020 11:54

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Read more
30 Dec 2019 15:39

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

Read more
30 Dec 2019 10:56

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Read more
11 Dec 2019 13:42

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

Read more
11 Dec 2019 10:45

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Read more
29 Nov 2019 10:23

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Read more
28 Nov 2019 11:56

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Read more
21 Nov 2019 12:56

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Read more
8 Nov 2019 10:30

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.